Arbutus Biopharma ABUS

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.06 (-1.78%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Arbutus Biopharma (ABUS)
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $3.31

  • Market Cap

    $624.87 Million

  • Price-Earnings Ratio

    -33.10

  • Total Outstanding Shares

    188.78 Million Shares

  • Total Employees

    73

  • Dividend

    No dividend

  • IPO Date

    July 26, 2007

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    701 veterans circle, Warminster, PA, 18974

  • Homepage

    http://www.arbutusbio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-11.99 Million
Net Cash Flow From Financing Activities, Continuing$1.77 Million
Net Cash Flow From Investing Activities$-11.99 Million
Net Cash Flow, Continuing$-30.95 Million
Net Cash Flow From Operating Activities, Continuing$-20.74 Million
Net Cash Flow From Financing Activities$1.77 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0
Income/Loss From Continuing Operations Before Tax$1.34 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Income/Loss From Continuing Operations After Tax$-19.72 Million
Revenues$1.34 Million
Other Operating Expenses$8.51 Million

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Parent$-19.50 Million
Other Comprehensive Income/Loss$-19.50 Million
Comprehensive Income/Loss$-19.50 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Noncurrent Liabilities$14.63 Million
Assets$140.44 Million
Equity$106.89 Million
Long-term Debt$0
Current Liabilities$18.92 Million
Equity Attributable To Parent$106.89 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ABUS from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.